Filter announcements
Loading...
RPG Life Sciences Ltd is engaged in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs) in the domestic and international market.The company is a part of RPG group which is a diversified conglomerate with interests in areas of infrastructure, tyres, information technology, pharmaceuticals, energy and plantations.The group is headed by Harsh Goenka.
RPG Life Sciences has strategically spun off its Active Pharmaceutical Ingredients (API) business into a new subsidiary, RPG Active Pharma (RPGAP). This move aims for sharper focus and growth. The API unit recorded ~95.1 Cr in external sales in FY26, specializing in high-value niche products. In a key development, RPGAP...
RPG Life Sciences reported a robust Q1 FY27, with revenue climbing 15.8% to ₹195.7 Cr and profit after tax (PAT) up 17.0% to ₹30.8 Cr, achieving a 15.7% PAT margin. Domestic Formulations (DF) led sales, growing 14.8% and contributing 68.3% of total revenue. International Formulations (IF) saw a 7.7% increase,...
RPG Life Sciences delivered robust FY26 results, with revenue growing 8.3% YoY to ₹707.5 Cr. Domestic Formulations, contributing 69% of sales, was a key performer, growing 1.6x faster than the Indian Pharma Market and ranking as the 4th fastest-growing company in IPM during Q4. Strong profitability led to an EBITDA...
Here is the financial summary for RPG Life Sciences: **Business Performance:** RPG Life Sciences delivered robust Q4 FY26, with revenue jumping 23.6% to 176.9 Cr and PAT (excluding exceptional items) soaring 58.1% to 29.3 Cr. For FY26, revenue grew 8.3% to 707.5 Cr. Domestic Formulations led performance, up 13.7% for...
RPG Life Sciences reported H1 FY26 revenue of 350.6 Cr, up 3.8% year-over-year (YoY), with Q2 revenue growing 5.5% YoY to 181.7 Cr. However, profit after tax (PAT) saw a 6.0% YoY decline in H1 to 54.8 Cr and a 9.6% decline in Q2 to 28.5 Cr, indicating margin pressure....